Ras isoprenylation and pAkt inhibition by zoledronic acid and fluvastatin enhances paclitaxel activity in T24 bladder cancer cells

Cancers

Volumn 3, Issue 1, 2011, Pages 662-674

  Li, Shaojuan ^a   de Souza, Paul ^a,b,c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

AKT; Ras; Signaling; Synergy; Taxanes

Indexed keywords

BETA ACTIN; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PROTEIN KINASE B; RAP PROTEIN; RAS PROTEIN; ZOLEDRONIC ACID;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; ISOPRENYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; WESTERN BLOTTING;

EID: 79953692706     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010662     Document Type: Article

References (30)

1. Adamson, P.; Marshall, C.J.; Hall, A.; Tilbrook, P.A. Post-translational modifications of p21rho protei ns. J. Biol. Chem. 1992, 267, 20033-20038.
2. Kato, K.; Cox, A.D.; Hisaka, M.M.; Graham, S.M.; Buss, J.E.; Der, C.J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA 1992, 89, 6403-6407.
3. Magee, T.; Marshall, C. New insights into the interaction of Ras with the plasma membrane. Cell 1999, 98, 9-12.
4. Khosravi-Far, R.; Cox, A.D., Kato, K.; Der, C.J. Protein prenylation: Key to ras function and cancer intervention? Cell Growth Difer. 1992, 3, 461-469.
5. Zhang, F.L.; Casey, P.J. Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransf erase type-I. Biochem. J. 1996, 320, 925-932.
6. Eastman, R.T.; Buckner, F.S.; Yokoyama, K.; Gelb, M.H.; VanVoorhis, W.C. Thematic review series: Lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J. Lipid Res. 2006, 47, 233-240.
7. Yan, J.; Roy, S.; Apolloni, A.; Lane, A.; Hancock, J.F. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. 1998, 273, 24052-24056.
8. Caron, R.W.; Yacoub, A.; Li, M.; Mitchell, C.; Hong, Y.; Hawkins, W.; Sasazuki, T.; Shirasawa, S.; Kozikowski, A.P.; Dennis, P.A.; Hagan, M.P.; Grant, S.; Dent, P. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol. Cancer Ther. 2005, 4, 257-270.
9. Macaluso, M.; Russo, G.; Cinti, C.; Bazan, V.; Gebbia, N.; Russo, A. Ras family genes: An interesting link between cell cycle and cancer. J. Cell Physiol. 2002, 192, 125-130.
10. Fontana, D.; Bellina, M.; Scoffone, C.; Cagnazzi, E.; Cappia, S.; Cavallo, F.; Russo, R.; Leonardo, E. Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur. Urol. 1996, 29, 470-476.
11. Saito, S.; Hata, M.; Fukuyama, R.; Sakai, K.; Kudoh, J.; Tazaki, H.; Shimizu, N. Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int. J. Urol. 1997, 4, 178-185.
12. Olderoy, G.; Daehlin, L.; Ogreid, D. Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res. 1998, 18, 2675-2678.
13. Reddy, E.P.; Reynolds, R.K.; Santos, E.; Barbacid, M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982, 300, 149-152.
14. Dunford, J.E.; Thompson, K.; Coxon, F.P.; Luckman, S.P.; Hahn, F.; Poulter, C.D.; Ebetino, F.H.; Rogers, M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296, 235-242.
15. Rubinstein, L.V.; Shoemaker, R. H.; Paull, K.D.; Simon, R.M.; Tosini, S.; Skehan, P.; Scudiero, D.A.; Monks, A.; Boyd, M.R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 1990, 82, 1113-1118.
16. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
17. Jagdev, S.P.; Coleman, R.E.; Shipman, C. M.; Rostami, H.A.; Croucher, P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br. J. Cancer. 2001, 84, 1126-1134.
18. Goffinet, M.; Thoulouzan, M.; Pradines, A.; Lajoie-Mazenc, I.; Weinbaum, C.; Faye, J.C.; Séronie-Vivien, S. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostati c cells. BMC Cancer. 2006, 6, 60.
19. Guo, R. T.; Cao, R.; Liang, P.H.; Ko, T.P.; Chang, T.H.; Hudock, M.P.; Jeng, W.Y.; Chen, C.K.; Zhang, Y.; Song, Y.; Kuo, C.J.; Yin, F.; Oldfield, E.; Wang, A.H. Bisphosphonates target multiple sites in both cis-and trans-prenyltransferases. Proc. Natl. Acad. Sci. USA 2007, 104, 10022-10027.
20. Kusama, T.; Mukai, M.; Tatsuta, M.; Matsumoto, Y.; Nakamura, H.; Inoue, M. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clin. Exp. Metastasis 2003, 20, 561-567.
21. Szabo, C.M.; Matsumura, Y.; Fukura, S.; Martin, M. B.; Sanders, J. M.; Sengupta, S.; Cieslak, J.A.; Loftus, T.C.; Lea, C.R.; Lee, H.J.; Koohang, A.; Coates, R.M.; Sagami, H.; Oldfield, E. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: A potential route to new bone antiresorption and antiparasitic agents. J. Med. Chem. 2002, 45, 2185-2196.
22. Plas, D.R.; Thompson, C.B. Akt-dependent transformation: There is more to growth than just surviving. Oncogene 2005, 24, 7435-7442.
23. Tokunaga, E.; Oki, E.; Egashira, A.; Sadanaga, N.; Morita, M.; Kakeji, Y.; Maehara, Y. Deregulation of the Akt pathway in human cancer. Curr. Cancer Drug Tar. 2008, 8, 27-36.
24. Chen, J.G.; Horwitz, S.B. Differential mitotic responses to microtubule-stabilizing and-destabilizing drugs. Cancer Res. 2002, 62, 1935-1938.
25. Lee, J.T.J.; Steelman, L.S.; McCubrey, J.A. Phosphatidylinositol 3'-ki nase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004, 64, 8397-8404.
26. Ding, S.; Chamberlain, M.; McLaren, A.; Goh, L.; Duncan, I.; Wolf, C.R. Cross-talk between signal ling pathways and the multidrug resistant protein MD R-1. Br. J. Cancer. 2001, 85, 1175-1184.
27. Danesi, R.; Figg, W.D.; Reed, E.; Myers, C.E. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosi s in PC-3 human prostate cancer cells. Mol. Pharmacol. 1995, 47, 1106-1111.
28. Hu, C.D.; Mariya, K.; Okada, T.; Qi, X.; Song, C.; Kataoka, T. Effect of phosphorylation on activities of Rap1A to interact with Raf-1 and to suppress Ras-dependent Raf-1 activation. J. Biol. Chem. 1999, 274, 48-51.
29. Smith, S.C.; Oxford, G.; Baras, A.S.; Owens, C.; Havaleshko, D.; Brautigan, D.L.; Safo, M.K.; Theodorescu, D. Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin. Cancer Res. 2007, 13, 3803-3813.
30. Oxford, G.; Owens, C.R.; Titus, B.J.; Foreman, T.L.; Herlevsen, M.C.; Smith, S.C.; Theodorescu, D. RalA and RalB: Antagonistic relatives in cancer cell migration. Cancer Res. 2005, 65, 7111-7120.